不依从EVAR术后监测的安全性影响:系统综述与Meta分析
估计平均不依从率为42.0%(95%CI 28-56%)。依从患者再干预率在术后3至5年显著更高,但全因死亡率和动脉瘤相关死亡率在术后5年内无统计学显著差异。
要点
- EVAR术后监测不依从率估计为42.0%,提示监测依从性普遍欠佳。
- 依从监测的患者再干预率在术后3至5年显著高于不依从患者。
- 术后5年内全因死亡率和动脉瘤相关死亡率在依从与不依从患者间无显著差异。
核心结论
- 依从EVAR监测的患者再干预率可能更高,但生存率并未优于不依从患者。
研究设计与样本
- 系统综述与Meta分析,遵循PRISMA指南,检索Embase、MEDLINE、Cochrane和Web of Science数据库1990年至2017年7月。
- 3项研究(8,316例)用于再干预率比较Meta分析,4项研究(12,995例)用于动脉瘤相关死亡率Meta分析。
主要发现
- 估计平均不依从率为42.0%(95%CI 28-56%)。
- 全因死亡率在术后1年(OR 5.77,95%CI 0.74-45.14)、3年(OR 2.28,95%CI 0.92-5.66)和5年(OR 1.81,95%CI 0.88-3.74)在依从与不依从患者间无统计学显著差异。
- 动脉瘤相关死亡率在依从与不依从患者间无统计学显著差异(OR 1.47,95%CI 0.99-2.19)。
- 依从患者再干预率在术后3年(OR 3.94,95%CI 1.46-10.69)和5年(OR 5.34,95%CI 1.87-15.29)显著高于不依从患者,1年时无显著差异(OR 6.36,95%CI 0.23-172.73)。
临床怎么用
- 临床应重视EVAR术后监测依从性管理,不依从率较高。
- 依从监测可能增加再干预,但未显示生存获益,需个体化评估监测策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE/BACKGROUND: Increasingly, reports show that compliance rates with endovascular aneurysm repair (EVAR) surveillance are often suboptimal. The aim of this study was to determine the safety implications of non-compliance with surveillance. METHODS: The study was carried out according to the Preferred Items for Reporting of Systematic Reviews and Meta-Analyses (PRISMA) guidelines. An electronic search was undertaken by two independent authors using Embase, MEDLINE, Cochrane, and Web of Science databases from 1990 to July 2017. Only studies that analysed infrarenal EVAR and had a definition of non-compliance described as weeks or months without imaging surveillance were analysed. Meta-analysis was carried out using the random-effects model and restricted maximum likelihood estimation. RESULTS: Thirteen articles (40,730 patients) were eligible for systematic review; of these, seven studies (14,311 patients) were appropriate for comparative meta-analyses of mortality rates. Three studies (8316 patients) were eligible for the comparative meta-analyses of re-intervention rates after EVAR and four studies (12,995 patients) eligible for meta-analysis for abdominal aortic aneurysm related mortality (ARM). The estimated average non-compliance rate was 42.0% (95% confidence interval [CI] 28-56%). Although there is some evidence that non-compliant patients have better survival rates, there was no statistically significant difference in all cause mortality rates (year 1: odds ratio [OR] 5.77, 95% CI 0.74-45.14; year 3: OR 2.28, 95% CI 0.92-5.66; year 5: OR 1.81, 95% CI 0.88-3.74) and ARM (OR 1.47, 95% CI 0.99-2.19) between compliant and non-compliant patients in the first 5 years after EVAR. The re-intervention rate was statistically significantly higher in compliant patients from 3 to 5 years after EVAR (year 1: OR 6.36, 95% CI 0.23-172.73; year 3: OR 3.94, 85% CI 1.46-10.69; year 5: OR 5.34, 95% CI 1.87-15.29). CONCLUSION: This systematic review and meta-analysis suggests that patients compliant with EVAR surveillance programmes may have an increased re-intervention rate but do not appear to have better survival rates than non-compliant patients.
引用
- Grima MJ, Boufi M, Law M, et al. Editor's Choice - The Implications of Non-compliance to Endovascular Aneurysm Repair Surveillance: A Systematic Review and Meta-analysis. Eur J Vasc Endovasc Surg. 2018. PMID: 29307756. doi:10.1016/j.ejvs.2017.11.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。